Items where authors include "Hanna, G.G."

Article

Fennell, D.A. orcid.org/0000-0001-7373-1312, Hill, K. orcid.org/0000-0001-5289-4454, Zhang, M. et al. (37 more authors) (2025) Constitutive inflammation and epithelial-mesenchymal transition dictate sensitivity to nivolumab in CONFIRM: a placebo-controlled, randomised phase III trial. Nature Communications, 16 (1). 6688. ISSN 2041-1723

Thippu Jayaprakash, K., Hanna, G.G. and Hatton, M.Q. (2022) Lung cancer in 2022 and beyond! Clinical Oncology, 34 (11). pp. 695-697. ISSN 0936-6555

Salem, A., Franks, K., Greystoke, A. et al. (6 more authors) (2022) Unaccounted confounders limit the ability to draw conclusions from big data analysis comparing radiotherapy fractionation regimens in NSCLC. Journal of Thoracic Oncology, 17 (6). e55-e56. ISSN 1556-0864

Diez, P., Hanna, G.G., Aitken, K.L. et al. (18 more authors) (2022) UK 2022 Consensus on Normal Tissue Dose-Volume Constraints for Oligometastatic, Primary Lung and Hepatocellular Carcinoma Stereotactic Ablative Radiotherapy. Clinical Oncology, 34 (5). pp. 288-300. ISSN 0936-6555

Fennell, D.A., Griffiths, G., Ottensmeier, C. et al. (4 more authors) (2022) CONFIRM trial: what is the real efficacy of second-line immunotherapy in mesothelioma? – Authors' reply. The Lancet Oncology, 23 (1). e14-e15. ISSN 1470-2045

Fennell, D.A., Ewings, S., Ottensmeier, C. et al. (36 more authors) (2021) Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial. The Lancet Oncology, 22 (11). pp. 1530-1540. ISSN 1470-2045

Haslett, K., Franks, K., Hanna, G.G. et al. (12 more authors) (2016) Protocol for the isotoxic intensity modulated radiotherapy (IMRT) in stage III non-small cell lung cancer (NSCLC): a feasibility study. BMJ Open, 6 (4). e010457. e010457-e010457. ISSN 2044-6055